PCR @ TCT 2019

Get the European perspective on the TCT 2019 Scientific Sessions

Late-breaking Clinical Trials covered:

• TWILIGHT: A randomized trial of ticagrelor monotherapy vs. ticagrelor-plus-aspirin beginning at 3 months in high-risk patients undergoing PCI, Roxana Mehran
• IDEAL-LM: A randomized trial of a bioabsorbable polymer DES with 4-month DAPT vs. a durable polymer DES with 12-month DAPT in patients with left main coronary artery disease, Robert-Jan Van Geuns
• SCOPE I: A randomized trial of the ACURATE Neo vs. the SAPIEN 3 bioprosthesis in patients with severe aortic stenosis, Jonas Lanz
• TriValve: A propensity score-matched analysis of transcatheter tricuspid valve treatment vs. medical treatment in patients with severe tricuspid regurgitation
• COAPT: 3-year outcomes from a randomized trial of the MitraClip in patients with heart failure and severe secondary mitral regurgitation, Michael J. Mack
• EXCEL: 5-year outcomes from a randomized trial of PCI vs. CABG in patients with left main coronary artery disease, Gregg W. Stone

Salvatore Brugaletta, Hospital Clinic, Barcelona, Tom Cahill, John Radcliffe Hospital, Oxford, Christopher Cook, Hammersmith Hospital, London, Nicole Karam, European Hospital Georges Pompidou, Paris, Luis Ortega-Paz, Clinical and Provincial Hospital of Barcelona, and Fabien Praz, Bern University Hospital, will provide you with condensed take-home messages from this meeting.

Cardio Polls

Participate in these polls ahead of TCT 2019! What do you expect and how will results affect your practice?

• SCOPE I and PORTICO randomized trials - comparison of TAVI bioprostheses
• TRIVALVE - transcatheter treatment of tricuspid regurgitation versus medical therapy 
• Alternative access in TAVI for patients unsuitable for transfemoral approach
• Will EXCEL 5-year change your practice?